Literature DB >> 10340534

Responses to oral delta9-tetrahydrocannabinol in frequent and infrequent marijuana users.

J M Kirk1, H de Wit.   

Abstract

It is known that an individual's drug use history affects the quality of subjective effects experienced following administration of several clinically used psychoactive drugs such as barbiturates, diazepam, and morphine. However, it is not known whether drug use history also affects responses to therapeutic cannabinoids such as delta9-THC. The current experiment compared the subjective and behavioral effects of oral delta9-THC in two groups of volunteers: frequent users (FREQ; n = 11), who reported using marijuana at least 100 times, and infrequent users (INF; n = 10) who reported using marijuana 10 or fewer times. Subjects participated in three sessions during which they received delta9-THC (7.5 and 15 mg) and placebo. They completed subjective effects questionnaires for 5 h following administration. In the FREQ group, the lower dose (7.5 mg) increased ratings of "feel drug," relative to placebo, whereas it had no effect in the INF group. In contrast, at the higher dose (15 mg), ratings of "feel drug" were lower in the FREQ group than in the INF group, suggestive of tolerance. In addition, the INF group reported greater sedative effects than the FREQ group following the higher dose of delta9-THC, again suggesting tolerance to delta9-THC's sedative effects. These findings demonstrate that marijuana use history may affect the subjective effects of oral delta9-THC, but that the influence of drug use history depends on the dose of drug administered. These findings may have implications for the clinical use of delta9-THC and other cannabinoids.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10340534     DOI: 10.1016/s0091-3057(98)00264-0

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  31 in total

1.  Cannabinoid modulation of subgenual anterior cingulate cortex activation during experience of negative affect.

Authors:  Christine A Rabinak; Chandra Sekhar Sripada; Mike Angstadt; Harriet de Wit; K Luan Phan
Journal:  J Neural Transm (Vienna)       Date:  2011-12-11       Impact factor: 3.575

2.  Dose-related differences in the regional pattern of cannabinoid receptor adaptation and in vivo tolerance development to delta9-tetrahydrocannabinol.

Authors:  Diana L McKinney; Michael P Cassidy; Lauren M Collier; Billy R Martin; Jenny L Wiley; Dana E Selley; Laura J Sim-Selley
Journal:  J Pharmacol Exp Ther       Date:  2007-10-29       Impact factor: 4.030

Review 3.  The endocannabinoid system as a target for modelling psychosis.

Authors:  Dagmar Koethe; Carolin Hoyer; F Markus Leweke
Journal:  Psychopharmacology (Berl)       Date:  2009-06-16       Impact factor: 4.530

Review 4.  The state of clinical outcome assessments for cannabis use disorder clinical trials: A review and research agenda.

Authors:  Mallory J E Loflin; Brian D Kiluk; Marilyn A Huestis; Will M Aklin; Alan J Budney; Kathleen M Carroll; Deepak Cyril D'Souza; Robert H Dworkin; Kevin M Gray; Deborah S Hasin; Dustin C Lee; Bernard Le Foll; Frances R Levin; Joshua A Lile; Barbara J Mason; Aimee L McRae-Clark; Ivan Montoya; Erica N Peters; Tatiana Ramey; Dennis C Turk; Ryan Vandrey; Roger D Weiss; Eric C Strain
Journal:  Drug Alcohol Depend       Date:  2020-04-26       Impact factor: 4.492

5.  Withdrawal from THC during adolescence: sex differences in locomotor activity and anxiety.

Authors:  Lauren C Harte-Hargrove; Diana L Dow-Edwards
Journal:  Behav Brain Res       Date:  2012-03-05       Impact factor: 3.332

Review 6.  Cannabis regulatory science: risk-benefit considerations for mental disorders.

Authors:  Jacob T Borodovsky; Alan J Budney
Journal:  Int Rev Psychiatry       Date:  2018-05-29

Review 7.  Cognitive function as an emerging treatment target for marijuana addiction.

Authors:  Mehmet Sofuoglu; Dawn E Sugarman; Kathleen M Carroll
Journal:  Exp Clin Psychopharmacol       Date:  2010-04       Impact factor: 3.157

Review 8.  Cannabinoids and Epilepsy.

Authors:  Evan C Rosenberg; Richard W Tsien; Benjamin J Whalley; Orrin Devinsky
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

9.  Tolerance to effects of high-dose oral δ9-tetrahydrocannabinol and plasma cannabinoid concentrations in male daily cannabis smokers.

Authors:  David A Gorelick; Robert S Goodwin; Eugene Schwilke; David M Schwope; William D Darwin; Deanna L Kelly; Robert P McMahon; Fang Liu; Catherine Ortemann-Renon; Denis Bonnet; Marilyn A Huestis
Journal:  J Anal Toxicol       Date:  2012-10-16       Impact factor: 3.367

10.  Acute effects of cannabis on breath-holding duration.

Authors:  Samantha G Farris; Jane Metrik
Journal:  Exp Clin Psychopharmacol       Date:  2016-08       Impact factor: 3.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.